BCL2 and B-cell chronic lymphocytic leukemia: Consequently, we were not able to include in Treatment node the emerging treatment options such as BTKi or BCL2 inhibitors, despite the fact that they appeared in the newest recommendations for the first-line treatment in patients with CLL.